BB	Anel A, Pardo Jimeno J, Antón Torres A. Inmunología tumoral e inmunoterapia del cáncer. 1ª ed. Zaragoza, Amazing books, 2018
BB	Brahmer JR, Lacchetti C, Schneider BJ, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of clinical oncology clinical practice guideline. J Clin Oncol 2018;36:1714–68.
BB	Davide Ippolito, Cesare Maino, Maria Ragusi, et al. Immune response evaluation criteria in solid tumors for assessment of atypical responses after immunotherapy. World J Clin Oncol 2021;12(5): 323-334
BB	Joo Hyun O, Martin A. Lodge, Richard L. Wahl. Practical PERCIST: A Simplified Guide to PET Response Criteria in Solid Tumors 1.01. Radiology 2016;280(2):576-584
BB	Julie R Brahmer, Hamzah Abu-Sbeih, Paolo Antonio Ascierto, et al. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events. J Immunother Cancer 2021;9(6):e002435
BB	Lesley Seymour, Jan Bogaerts, Andrea Perrone, et al. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol 2017;18:e143-152
BB	Lucy Boyce Kennedy MD, April K. S. Salama. A review of cancer immunotherapy toxicity. CA Cancer J Clin 2020;70:86-104
BB	Puzanov I, Diab A, Abdallah K, et al. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. J Immunother Cancer. 2017;5(1):95
BB	Thorsten Persigeh, Simon Lennartz and Lawrence H. Schwartz. iRECIST: how to do it. Cancer Imaging 2020;20:2
BB	Wahl RL, Jacene H, Kasamon Y, Lodge MA. J Nucl Med. 2009;50 Suppl 1(Suppl 1):122S-50S